Biobanks AMERICA

Atherosclerosis Risk in Communities: four U.S. community cohorts with longitudinal cardio-metabolic phenotyping and genome-wide genotype data; foundational for many cardiovascular and multi-ancestry GWAS.

The All of Us Research Program is a historic effort to collect and study data from one million or more people living in the United States. The goal of the program is better health for all of us. The program began national enrollment in 2018 and is expected to last at least 10 years.

The Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai is leading the movement toward diagnosis and classification of disease according to the patient’s molecular profile. This approach accommodates differences at all possible levels of exposure (genome, environment, and lifestyle) and at all stages of the process, from prevention to post-treatment follow-up. At the center of this effort is BioMe, an electronic medical record-linked biobank that enables researchers to rapidly and efficiently conduct genetic, epidemiologic, molecular, and genomic studies on large collections of research specimens linked with medical information.

BioPortal is a unique research platform at the Jewish General Hospital (JGH)/Lady Davis Institute in Montreal built in partnership with the CERC Chair in Genomic Medicine at McGill.

Planning for BioVU began in mid-2004 and the first samples were collected in February 2007. Prior to collecting DNA samples, all aspects of the BioVU project were extensively tested. BioVU now accrues 500-1000 samples per week, totaling more than 275,000 DNA samples as of January 2022. Vanderbilt clinic patients may sign the BioVU Consent Form if they wish to donate their excess blood samples, or not sign the form if they do not wish to participate.

Biobank consented samples with associated clinical data from diverse populations from throughout the United States and Latin America via healthcare and biopharma partnerships.

CARTaGENE is a public research platform of the CHU Sainte-Justine aiming to accelerate health research. CARTaGENE is made up of both biological samples and data on the health and lifestyle of 43,000 Quebec men and women between the ages of 40 and 69 at recruitment.

The Ontario Health Study (OHS) is a resource for investigating the ways in which lifestyle, the environment and genetics affect people’s health. It is one of the regional cohorts that collectively form the Canadian Partnership for Tomorrow’s Health (CanPath)—a pan-Canadian cohort with >330 000 participants. The linking of Canada’s rich collection of administrative health data with the cohort’s data represents a powerful means to disseminate high-quality, timely data.

Established in 2014 as a partnership between UCHealth and University of Colorado Anschutz Medical Campus, the Colorado Center for Personalized Medicine (CCPM) brings together multiple disciplines and institutions to uncover advancements in genomics that can improve diagnosis and treatment of disease, and identify more tailored approaches to population health management.To facilitate discoveries in personalized medicine, CCPM has created a Biobank that aims to be one of the largest academic medicine biospecimen repositories in the mountain and midwest regions of the U.S. The CCPM Biobank is able to link biospecimens and genotype information with patient health information from electronic medical records in an enterprise data warehouse (Health Data Compass) to support a broad range of research, operational, and clinical quality improvement agendas.

Brazilian Longitudinal Study of Adult Health: six centers with deep phenotyping and biosamples; genome-wide data used for cardiometabolic and population-genetics GWAS in Brazil.

Hispanic Community Health Study / Study of Latinos: four U.S. field centers with deep cardiometabolic phenotyping; central to GWAS in admixed Latino populations.

Multi-Ethnic Study of Atherosclerosis: six U.S. sites with subclinical CVD imaging and omics; genome-wide data widely used in multi-ethnic GWAS and cardiometabolic genetics.

The Mass General Brigham Biobank is a large research program designed to help researchers understand how people’s health is affected by their genes, lifestyle, and environment. By participating in the Mass General Brigham Biobank, you can help us better understand, treat, and even prevent the diseases that might affect your health and the health of future generations.

Between 1998 and 2004, CTSU, in collaboration with the Mexican Ministry of Health, established a study in Mexico City, in which over 150,000 middle-aged adults (including 100,000 women and 50,000 men) provided information about their lifestyle and disease history, had physical measurements recorded (including weight, waist and hip circumference, blood pressure) and had a blood sample taken.

The Michigan Genomics Initiative (MGI) is a collaborative research effort among physicians, researchers, and patients at the University of Michigan (U-M) with the goal of combining patient electronic health record (EHR) data with corresponding genetic data to gain novel biomedical insights. There are currently ~84K consented participants through the MGI and partner studies and the addition of ~10K new participants per year is anticipated. Currently, all MGI participants with available genetic data have received care at the University of Michigan Health System.

The Million Veteran Program (MVP) is a national research program to learn how genes, lifestyle, and military exposures affect health and illness. Since launching in 2011, over 900,000 Veteran partners have joined one of the world's largest programs on genetics and health.

Population Architecture using Genomics and Epidemiology (PAGE): NIH consortium coordinating genome-wide association studies in African American, Hispanic/Latino, Asian, Pacific Islander, and Native American participants across multiple cohorts.

The Penn Medicine BioBank (PMBB) is a research program created to study the causes and treatments of many diseases. Any Penn Medicine patient (age 18 and up) can sign up. The PMBB is a collection of biological samples, such as blood or tissue, that are donated by patient volunteers. These samples are then connected to clinical information, such as diseases or lab measures. These data are then used by researchers to discover new ways to detect, treat, and maybe even prevent or cure disease. Some of these studies may be about how genes affect health and disease. Other studies look at how genes affect response to medicines.

The Canadian Longitudinal Study on Aging (CLSA) is a large, national, long-term study that will follow approximately 50,000 individuals who are between the ages of 45 and 85 when recruited, for at least 20 years. The CLSA will collect information on the changing biological, medical, psychological, social, lifestyle and economic aspects of people’s lives. These factors will be studied to understand how, individually and in combination, they have an impact in both maintaining health and in the development of disease and disability as people age.

The UCLA ATLAS Precision Health Biobank, under the supervision of the Translational Pathology Core Laboratory (TCPL), collects biological samples from patients who have consented to participate in the UCLA ATLAS Community Health Initiative. As a collaborator with UCLA ATLAS Community Health Initiative, the UCLA ATLAS Precision Health Biobank manages the collection and distribution of biological samples by removing the personally identifiable information.

Large U.S. women’s health trial and observational study with biospecimens and long follow-up; genotype data support GWAS on cancer, cardiovascular, and aging-related traits.